



Published in final edited form as:

Prev Med. 2019 October ; 127: 105798. doi:10.1016/j.ypmed.2019.105798.

The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial

Monica L. Kasting^{a,*}, Katharine J. Head^b, Dena Cox^c, Anthony D. Cox^c, Gregory D. Zimet^d

^aPurdue University, Department of Health and Kinesiology, 800 W. Stadium Ave., West Lafayette, IN 47907, United States

^bIndiana University-Purdue University Indianapolis, Department of Communication Studies, 425 University Boulevard, Indianapolis, IN 46202, United States

^cIndiana University Kelley School of Business, 801 W. Michigan Street, Indianapolis, IN 46202, United States

^dIndiana University School of Medicine, Department of Pediatrics, 410 W. 10th Street, Indianapolis, IN 46202, United States

Abstract

Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3×2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1,747 participants, 47.7% (n=833) received 0 doses of HBV vaccine, 27.8% (n=485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation ($p=.59$). Mean number of doses received by the gain-framed group ($m=.96$) was not significantly different from the loss-framed group ($m=.97$, $RR=.99$, 95% $CI=.88-1.12$). However, those receiving any framing message received significantly more doses ($m=.96$) than those in the control condition ($m=.81$, $RR=1.17$, 95% $CI=1.06-1.31$). Participants who received a HCP recommendation received significantly more vaccine doses ($m=.95$) than those in the vaccine-offered condition (mean=.82, $RR=1.16$, 95% $CI=1.05-1.28$). These results suggest there is

*Corresponding author: mlkasting@purdue.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinicaltrials.gov Identifier: . Registration date: August 20, 2008.

Conflict of Interest Statement

Gregory D. Zimet has received honoraria from Sanofi Pasteur for his work on the Adolescent Immunization Initiative and has received an honorarium and travel funding from Merck to present at a meeting about HPV vaccination. The other authors have no relevant conflicts of interest to disclose.

no difference in vaccine uptake between gain-frame and loss-frame messages, but both are better than a control message. These results also support advising HCP to provide a strong recommendation for vaccinations beyond merely offering it to patients. This study has implications for vaccine uptake beyond HBV, and can inform future research on effective vaccine communication research.

Keywords

Prospect Theory; hepatitis b virus; hepatitis B vaccines; vaccination; vaccine uptake; health communication; patient acceptance of healthcare; randomized controlled trial; health promotion; framing

Introduction

Despite clear evidence of effectiveness and safety, many adults in the United States have not received recommended vaccines and remain susceptible to vaccine-preventable diseases.¹ The National Vaccine Advisory Committee² and others^{3,4} note the importance of provider recommendation in adult vaccine receipt, yet there remains uncertainty regarding the structure and content of effective vaccine recommendations. This study presents a clinical intervention testing message framing and strength of provider recommendation on hepatitis B virus (HBV) vaccination receipt among previously unvaccinated adult patients attending sexually transmitted diseases (STD) clinics.

Framing

Rothman and Salovey⁵ interpreted Prospect Theory⁶ to suggest that messaging should be targeted on the perceived risk associated with a health behavior. They argued disease-prevention behaviors (e.g., vaccination) were low-risk, whereas disease-detection behaviors (e.g., mammography screening) were high-risk because of the potential for hearing bad news. The authors hypothesized disease-prevention behaviors could best be encouraged by gain-framed messages (i.e., emphasizing the advantages of a behavior), whereas disease-detection behaviors could be encouraged by loss-framed messages (i.e., emphasizing the disadvantages of forgoing disease detection). However, several research reports and meta-analytic reviews have presented persuasive theoretical and empirical refutations of this interpretation of Prospect Theory.^{7–16} Despite these critiques, both research and public health programs continue to use gain-framed messages for preventive behaviors and loss-framed messages for detection behaviors.^{17–20}

While vaccination is considered a disease-prevention (low-risk) behavior in terms of Prospect Theory, many individuals also perceive vaccination as a high-risk behavior (e.g. injection pain, vaccine side effects).²¹ Alternatively, strong arguments have been made that perceived risk/safety may be irrelevant with respect to message framing, particularly in light of the fact that “risk” in Prospect Theory refers to uncertainty, not to perceptions of harm.^{9,13,14} Given the public health importance of vaccination,²² it is essential to provide further evidence regarding the most effective message-framing approach for encouraging vaccination.

Provider Recommendation

In addition to message framing, consensus has grown that the strength of a healthcare provider's (HCP; e.g. physician, nurse practitioner) recommendation can substantially influence vaccination rates. While it is not known whether vaccine recommendation varies across types of HCP, it is clear a strong HCP recommendation is one of the best predictors of vaccination behavior in both parents (deciding for their children) and adults (deciding for themselves).^{23–25} However, *how* HCPs recommend vaccination may make a difference. Research suggests when HCPs use a presumptive approach to recommending vaccination (i.e., present vaccination as a default expectation) children and adolescents are more likely to get vaccinated.^{26–30} However, the evidence supporting presumptive recommendations is based on observational studies^{26–28}, cross-sectional self-report surveys or interviews,³¹ and interventions designed in a way that made it difficult to rigorously control the specific wording of the recommendation message delivered.^{32,33}

Current Study

The purpose of the present study was to evaluate the effects of message framing and HCP recommendation strength on HBV vaccination. HBV vaccine has been available for over 30 years.³⁴ It is a 3-dose series all children currently get starting at birth.³⁵ In 2017, 91.9% of adolescents aged 13–17 years had received all 3 HBV vaccine doses.³⁶ In contrast, only 48.6% of adolescents were up-to-date on human papillomavirus (HPV) vaccination.³⁶ Even though rates of childhood HBV vaccination are quite high, coverage among adults is variable, and vaccination is still recommended for high-risk adults (e.g., multiple sexual partners, injection drug users).³⁷ Though the data reported in this manuscript were collected 12–15 years ago, message communication around vaccine uptake in general and especially among at-risk populations remains a critical public health concern, as exemplified by outbreaks of vaccine-preventable diseases in the U.S.³⁸ This present study examines the effect of message framing and HCP recommendation on HBV vaccine uptake in a randomized controlled trial of previously unvaccinated adults. The study also explores potential moderators of vaccination behavior, including fear of shots, fear of vaccines, and perception of message framing.

Methods

Procedures and participants

Research staff recruited participants from three STD clinics, one in Indianapolis, IN and two in Chicago, IL from 2003 to 2007. Patients 18 years of age or older who were able to understand spoken English, were HBV and HIV negative (by self-report), and had never received HBV vaccine (by self-report) were eligible to participate. Patients who enrolled completed an audio, computer-assisted self-interview (ACASI) in a private setting. After completing the ACASI, participants were seen by a nurse practitioner for STD-related care and vaccine administration. The study was approved by the institutional review boards of Indiana University-Purdue University Indianapolis and the Chicago Department of Public Health. All participants provided written informed consent and were compensated \$20 for the time and effort involved in completing the ACASI.

Measures and Interventions

The ACASI assessed socio-demographic variables (age, sex, education, race, employment status, relationship status, and family income). In addition, potential moderators of framing effects included two scales adapted from a previous study on predictors of HBV vaccination: ³⁹ Fear of Shots and Fear of Vaccine, was measured using a 5-point response format ranging from Strongly Disagree to Strongly Agree. Fear of Shots had four items (e.g., “Getting shots can be scary”) and had good internal reliability (coefficient alpha = .79). Fear of vaccine had six items (e.g., “Hepatitis vaccine shots are dangerous”) and also had good internal reliability (coefficient alpha = .78).

There were three message framing conditions related to receiving HBV vaccine (Gain-Framed; Loss-Framed; Control) and two HCP recommendation conditions (Vaccine Offered; Vaccine Recommended), resulting in a 3 × 2 experimental design. A block randomization approach programmed into the ACASI ensured that for every block of 30 participants, 5 were assigned to each of the 6 experimental conditions. Participants and researchers were blinded to the framing intervention and participants, but not research staff, were blinded to the recommendation intervention.

Message Framing.—The message framing interventions were delivered via the ACASI. The gain-framed message emphasized the advantages of HBV vaccination, whereas the loss-framed message emphasized the disadvantages of not getting vaccinated. Both gain- and loss-framed messages involved non-narrative and narrative information (See Table 1 for examples). Narrative messages were targeted to the respondent’s sex (e.g., using a female name for female respondents, and a male name for male respondents). The control condition simply reiterated three basic facts about HBV vaccination that was provided to all participants: 1. HBV can be transmitted by unprotected sex and sharing needles; 2. A vaccine for HBV exists; and 3. The vaccine requires 3 shots over 6 months to be most effective at preventing infection. The messages appeared on the screen as text and participants had the option of having the ACASI read the text out loud to them through headphones.

As a manipulation check, we asked participants whether the message they received emphasized the benefits of receiving the HBV vaccine (i.e., gain-framed) or if it emphasized the risks associated with not receiving the vaccine (i.e., loss-framed).

HCP Recommendation.—The HCP interventions were delivered by the nurse practitioner at the end of the medical exam. Medical encounters were periodically audio-recorded to assess fidelity of intervention delivery. No problems with message delivery were identified through this process. The vaccine-offered message was, “We have free hepatitis B virus vaccine available. Would you like to get vaccinated?” The vaccine-recommended message was, “We have free hepatitis B virus vaccine available. I strongly recommend that you get vaccinated.”

Outcome.—The outcome of interest was number of HBV vaccine doses received (i.e., 0, 1, 2, or 3 doses received). For those who agreed to receive vaccination, the first dose was provided by the nurse practitioner after the recommendation was delivered. Participants were

sent reminders for second and third doses. Within the study protocol, participants were allowed up to eight months to complete the three-dose series.

Additional information on the study protocol is available at [Clinicaltrials.gov](https://clinicaltrials.gov) () or by contacting the senior author (GDZ).

Analyses

The sample size requirement was modeled based on a 6-group ANOVA design (3X2). In order to detect a small effect size ($f=0.1$),⁴⁰ setting power at 80% and the significance level at 0.05, a sample size of 200 per group would be required.⁴¹ The actual sample sizes across the six groups ranged from 284 to 299, indicating sufficient power to detect a small effect size in number of HBV vaccine doses, even with the use of poisson regression rather than ANOVA. The trial was stopped at the end of the funding period, after adequate power was achieved.

The primary outcome of interest was number of HBV vaccine doses received, which ranged from 0 to 3. We began by assessing whether there was an interaction between message framing and HCP recommendation. We then ran a series of Poisson regression analyses to assess the effect of message interventions on vaccine doses. The first set of analyses focused on direct evaluations of: 1. gain-framed vs. loss-framed messages; 2. framed vs. non-framed (i.e., control) messages; and 3. HCP recommended vaccine vs. HCP offered vaccine. The second set of analyses examined fear of shots and fear of vaccines as potential moderating factors influencing the association of message framing with vaccination. According to Prospect Theory, those who score high on fear of shots or fear of vaccine should be more responsive to a loss-framed message, whereas those who score low on fear of shots or fear of vaccine should be more responsive to a gain-framed message. The third set of analyses examined the effect of perceived message frame (perceived gain-framed vs. perceived loss-framed) on doses of vaccine.

Results

Sample Description

A total of 3336 patients were screened for participation, with 716 refusing to participate, 866 ineligible, and 3 who withdrew prior to randomization, leaving 1751 participants. The main reasons for refusal were lack of time or not interested. Primary reasons for ineligibility were report of prior HBV vaccination, HBV or HIV positive, and under 18 years of age. There were four computer failures, resulting in a final sample of 1747 participants. Of the final sample 7.2% (n=126) were collected in 2003, 29.4% (n=514) were collected in 2004, 28.4% (n=497) were collected in 2005, 25.5% (n=445) were collected in 2006, and 9.4% (n=165) were collected in 2007. Within the ACASI, 33.2% (n=580) were randomized to the gain-framed message, 33.4% (n=584) to the loss-framed message, and 33.4% (n=583) to the control group. After the ACASI, participants were re-randomized to either the provider-offered condition (n= 50.5%) or the provider-recommended condition (n = 49.5%). See Figure 1. The final sample was 60% male, 81.6% Black, and 18–80 years of age (Median = 29). For a full sample description by message framing and recommendation, see Table 2.

Of the 1747 participants, 47.7% (n = 833) refused vaccination. Of the 52.3% (n = 914) who received the first dose of vaccine, 46.9% (n = 429) returned for the second dose and 27.0% (n = 247) returned for the third dose. The main outcome variable, number of doses, breaks down as follows: 0 doses (n = 833; 47.7%); 1 dose (n = 485; 27.8%); 2 doses (n = 182; 10.4%); 3 doses (n = 247; 14.1%).

Intervention Group Comparisons at Baseline

To confirm the randomization procedure resulted in similar groups we carried out one-way analyses of variance for continuous variables and chi-square tests for categorical variables using data from the pre-intervention survey. The six groups (framing by provider recommendation type) were not significantly different (i.e., $p > 0.05$) with respect to age, gender distribution, education, race, employment status, relationship status, family income, or study site. In addition, there were no statistical differences on the two attitudinal measures, Fear of Shots and Fear of Vaccine (Table 2).

Message Framing and HCP Recommendation

We first tested the interaction of framing group with HCP recommendation group. The interaction was not significant (Wald Chi-Square = .30, $p = .59$, relative risk [RR] = .97 95% CI=.86–1.09), so all subsequent analyses examined only the main effects of the interventions. Those receiving a gain-framed message received a similar number of doses of vaccine (Mean=.96) as those receiving a loss-framed message (Mean=.97; Wald Chi-Square=.02, $p = .88$, RR=.99, 95% CI=.88–1.12). However, those receiving any framing message (either loss-framed or gain-framed) received significantly more doses (Mean=.96) than those in the control condition (Mean=.81; Wald Chi-Square=8.54, $p < .01$, RR=1.17, 95% CI=1.06–1.31). Similarly, participants in the vaccine-recommended condition received significantly more vaccine doses (Mean=.95) than those in the vaccine-offered condition (Mean=.82; Wald Chi-Square=8.47, $p < .01$, RR=1.16, 95% CI=1.05–1.28). Figures 2a and 2b illustrate the percent of the sample receiving each dose of HBV vaccine by message group and HCP recommendation, respectively.

Moderation Analyses for Message Framing

Results of the analysis showed no significant main effect for gain- vs. loss-framed message (Wald Chi-Square=1.68, $p = .20$, RR=1.44, 95% CI=.83–2.48) and no significant interactions of fear of shots (Wald Chi-Square=3.17, $p = .08$, RR=1.12, 95% CI=.83–1.24) or fear of vaccine (Wald Chi-Square=.03, $p = .86$, RR=1.02, 95% CI=.83–1.24) with message framing. Furthermore, the trend towards significance for fear of shots was in the opposite direction of that predicted by the theory. Among those receiving the loss-framed message, higher fear of shots was associated with fewer doses of vaccine ($r = -.13$, $p < .01$). Among those receiving the gain-framed message, there was no significant association of fear of shots with doses ($r = -.04$, $p = .30$). Overall, fear of shots was associated with fewer doses of vaccine received (Wald Chi-Square=6.48, $p < .05$, RR=.78, 95% CI=.65–.94). Fear of vaccines was not associated with vaccine receipt (Wald Chi-Square=3.06, $p = .08$, RR=.75, 95% CI=.55–1.04).

Perceived Message-Framing Analyses

Overall, message delivered was significantly associated with message perceived (Chi-Square=87.35, $p < .01$), but the Kappa statistic (.26) indicated only modest agreement between the two (see Figure 3). Of those who received the gain-framed message, 80.6% accurately reported the message emphasized the advantages of HBV vaccination (19.4% reported the message emphasized the disadvantages of not getting vaccinated). However, of those who received the loss-framed message, only 45.3% accurately reported the message emphasized the disadvantages of not getting HBV vaccination (54.7% reported the message emphasized the advantages of vaccination). Therefore, we examined whether perceived message frame, rather than intended message frame, might be associated with number of vaccine doses received. However we found no significant effect for perceived frame on vaccination (Wald Chi-Square=.57, $p=.45$, RR=.95, 95%CI=.84–1.08) and no significant interaction of fear of shots (Wald Chi-Square=.26, $p=.61$, RR=.97, 95%CI=.85–1.10) or fear of vaccine (Wald Chi-Square=.93, $p=.34$, RR=.90, 95%CI=.73–1.12) with perceived frame.

Discussion

The purpose of this study was to examine the effect of message framing and provider recommendation type on receipt of HBV vaccine. We found no support for the idea that a gain-framed message would be more effective than a loss-framed message for HBV vaccination. The lack of difference between gain- and loss-framed messaging remained consistent even when considering the potential moderating factors of fear of vaccine and fear of shots. Moreover, the results held even when the analysis focused on perceived framing condition. Our findings, therefore, are contrary to the interpretation of Prospect Theory proposed by Rothman and Salovey⁵ and consistent with the literature that finds no distinct pattern of results related to gain/loss message framing and health behavior with respect to vaccination. Few prior studies of message framing have included a control condition, relevant moderating factors, perceived frame, and a behavioral outcome. This study, therefore, represents a particularly thorough and rigorous evaluation of message framing.

We found that either framing condition was more effective than the information-only control condition. That is, framed messages depicting the health consequences of HBV vaccination behavior increased vaccine acceptance, regardless of whether those messages were gain-framed or loss-framed. However, it is not possible to tease out whether this effect is due to the persuasive nature of the frame, to the narrative contexts provided within each frame, or to both combined. The persuasive effects of narrative are well-documented, suggesting a narrative with fictional characters, but containing scientific facts, may lead participants to identify with the characters, and therefore feel more vulnerable to the disease.^{42,43} Indeed, another study found narrative evidence to be more effective in increasing perception of personal risk and intention to attain HBV vaccination when compared to statistics alone.⁴⁴

Prospect Theory was originally developed to assess behavioral economics.⁴⁵ The notion of “risk” in Prospect Theory has to do with uncertainty in the probability of an outcome, not the risk of a negative health outcome.⁴⁵ Therefore, it is problematic to attempt to apply this theory to a health outcome such as HBV vaccine, or to vaccination more broadly, because a health outcome “risk” is contextually different from economic risk. Furthermore, prevention

and early detection are not mutually exclusive behaviors. For example, many behaviors entail both prevention and early detection (e.g., colonoscopy). Also the domain of preventive behaviors is hardly homogeneous, entailing discrete, largely individually-determined behaviors (e.g., vaccination), repetitive, periodic behaviors (e.g., sunscreen use), daily, habitual behaviors (e.g., flossing or brushing teeth), and repetitive, socially-embedded behaviors (e.g., condom use). Therefore, it is difficult to broadly define a single health communication strategy that would work for prevention or early detection of disease.

We contend that defining all protective behaviors as “low-risk” and all detection behaviors as “high-risk” is an inaccurate overgeneralization and represents a top-down approach. As shown in this study, a substantial percentage of respondents perceived HBV vaccination as “high-risk” due to fear of the vaccine itself or fear of shots in general, indicating that, while Rothman and Salovey would define vaccination as “low-risk,” many participants did not interpret vaccination this way. It is also possible the messages that are delivered may not correspond to the patients’ perceptions of messages. In this study the majority of participants who received a loss-framed message interpreted the message as gain-framed, suggesting many of the participants cognitively recoded the message to be viewed in a positive light. This discrepancy points to the importance of manipulation checks to ensure the messages researchers construct are accurately interpreted by the recipients.

Patients in the vaccine-recommended group received more HBV vaccine doses than those in the vaccine-offered condition. The effect of HCP recommendation is not surprising and is consistent with prior research, including research on HPV vaccination, which identifies provider recommendation as a significant predictor of vaccination uptake.^{46–50} Future research should focus on continuing to identify the most relevant content to include in a strong provider recommendation, which may vary depending on the type of vaccination and population (e.g. HPV vaccination for adolescents, HBV vaccination for adults, etc.). Additionally, future research could explore any associations between the type of provider giving the recommendation (i.e. physician vs. nurse practitioner) on vaccine uptake.

This study has notable strengths and is a valuable addition to the literature. In particular, most of the research on provider recommendation and vaccine uptake relies on self-report data, or on broad clinical trials that could not precisely control for HCP recommendation delivery.^{26–28,31–33} Instead, this study involved controlled experimental manipulation of the recommendation conditions and examined actual vaccine uptake. While this study is a valuable addition to the scientific literature, there are limitations that may limit generalizability. First, participants for this study were recruited from public STD clinics, which tend to have a higher proportion of young, low income, male, racial/ethnic minority, and be at higher risk of STD infection compared to the general population. Second, the HCP in this study was a nurse practitioner and it is possible the results may differ if the recommendation was made by a physician. However, many research studies use the term “healthcare provider” and do not specify whether this is a physician or advanced practice professional (nurse practitioner, physician assistant). Similar to our study, these studies also show HCP recommendation is one of the strongest predictors of vaccine uptake,^{51,52} indicating these results are similar regardless of provider type. Third, due to intervening projects with the study team, there was a delay in analyzing and publishing these data.

Therefore, the data are older than is typical. While this may have implications for the specific STD services offered at the study clinics, and there may be fewer opportunities to provide HBV vaccination, the theory and implications of the results for framing interventions should not be diminished by the passage of time. Lastly, it is possible individuals' health beliefs may have had a moderating effect on the message framing. For example, previous research has shown message framing may have unintended negative effects for participants with certain preexisting health beliefs.⁵³ Future research should include health beliefs as possible moderators to a health communication intervention. Despite these limitations, this study adds to the growing body of literature suggesting there is no particular advantage of gain-framed messaging over loss-framed messaging (or vice-versa) for the preventive behavior of getting vaccinated against HBV.

Conclusion

This study demonstrated a framed message about the benefits of HBV vaccination (or risks of non-vaccination) may enhance vaccination rates in at-risk adults as compared to an unframed message, particularly in the context of a narrative. Further, as research on HPV vaccination has shown, the recommendation of a HCP is an important factor in motivating patients to accept vaccination.^{46–50} This study highlights the importance of the accurate operationalization of theoretical constructs (e.g., “risk”). Additionally, it calls attention to the importance of rigorous study design which should include having a control group and manipulation checks. The findings have implications for vaccine uptake beyond HBV vaccination and have research and clinical implications for vaccinations more broadly.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases (grant number: R01 AI49644–01A2, PI: Zimet, Study years: 2002–2008).

References

1. Williams W, Lu P, O'Halloran A, et al. Surveillance of Vaccination Coverage Among Adult Populations-United States, 2014. *Morbidity and mortality weekly report* 2016;66(NO. SS-11):1–28.
2. National Vaccine Advisory Committee. Recommendations from the National Vaccine Advisory Committee: Standards for Adult Immunization Practice. *Public Health Reports*. 2014;129(2):115–123. [PubMed: 24587544]
3. Malosh R, Ohmit SE, Petrie JG, Thompson MG, Aiello AE, Monto AS. Factors associated with influenza vaccine receipt in community dwelling adults and their children. *Vaccine*. 2014;32(16):1841–1847. [PubMed: 24530926]
4. Johnson DR, Nichol KL, Lipczynski K. Barriers to Adult Immunization. *The American Journal of Medicine*. 2008;121(7, Supplement 2):S28–S35.
5. Rothman AJ, Salovey P. Shaping perceptions to motivate healthy behavior: The role of message framing. *Psychological Bulletin*. 1997;121:3–19. [PubMed: 9000890]
6. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. *Science (New York, NY)*. 1981;221:453–458.
7. O'Keefe DJ, Jensen JD. The relative persuasiveness of gain-framed loss-framed messages for encouraging disease prevention behaviors: A meta-analytic review. *Journal of Health Communication*. 2007;12:623–644. [PubMed: 17934940]

8. O'Keefe DJ, Jensen JD. The relative persuasiveness of gain-framed and loss-framed messages for encouraging disease detection behaviors: A meta-analytic review. *Journal of Communication*. 2009;59:296–316.
9. Cox AD, Cox D, Zimet GD. Understanding consumer responses to product risk information. *Journal of Marketing*. 2006;70:79–91.
10. O'Keefe DJ, Nan X. The relative persuasiveness of gain- and loss-framed messages for promoting vaccination: a meta-analytic review. *Health Commun*. 2012;27(8):776–783. [PubMed: 22292904]
11. O'Keefe DJ, Wu D. Gain-framed messages do not motivate sun protection: a meta-analytic review of randomized trials comparing gain-framed and loss-framed appeals for promoting skin cancer prevention. *International journal of environmental research and public health*. 2012;9(6):2121–2133. [PubMed: 22829794]
12. Gallagher KM, Updegraff JA. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. 2012;43(1):101–116. [PubMed: 21993844]
13. Van 't Riet J, Cox AD, Cox D, et al. Does Perceived Risk Influence the Effects of Message Framing? A New Investigation of a Widely Held Notion. *Psychol Health*. 2014.
14. Van 't Riet J, Cox AD, Cox D, et al. Does perceived risk influence the effects of message framing? Revisiting the link between prospect theory and message framing. *Health psychology review*. 2016;10(4):447–459. [PubMed: 27062974]
15. Penta MA, Baban A. Message Framing in Vaccine Communication: A Systematic Review of Published Literature. *Health communication*. 2018;33(3):299–314. [PubMed: 28059557]
16. Frew PM, Saint-Victor DS, Owens LE, Omer SB. Socioecological and message framing factors influencing maternal influenza immunization among minority women. *Vaccine*. 2014;32(15):1736–1744. [PubMed: 24486366]
17. Centers for Disease Control and Prevention. 6 Reasons to Get HPV Vaccine for Your Child. In: 2018.
18. Centers for Disease Control and Prevention. Screen for Life Campaign Public Service Announcements. In:2018.
19. Nakamura R, Suhrcke M, Zizzo DJJT, Decision. A triple test for behavioral economics models and public health policy. 2017;83(4):513–533.
20. De Jaegher KJT, Decision. Strategic framing to influence clients' risky decisions. 2019;86(3):437–462.
21. Mouchet J, Salvo F, Raschi E, et al. Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. *Vaccine*. 2018;36(12):1548–1555. [PubMed: 29454521]
22. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. *Bull World Health Organ*. 2008;86(2):140–146. [PubMed: 18297169]
23. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. *American Journal of Medicine*. 2008;121:S28–S35.
24. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to Human Papillomavirus Vaccination Among US Adolescents: A Systematic Review of the Literature. *JAMA Pediatr*. 2014;168(1):76–82. [PubMed: 24276343]
25. Williams WW, Lu PJ, O'Halloran A, et al. Noninfluenza vaccination coverage among adults - United States, 2012. *MMWR Morbidity and mortality weekly report*. 2014;63(5):95–102. [PubMed: 24500288]
26. Opel DJ, Heritage J, Taylor JA, et al. The Architecture of Provider-Parent Vaccine Discussions at Health Supervision Visits. *Pediatrics*. 2013;132(6):1037–1046. [PubMed: 24190677]
27. Sturm L, Donahue K, Kasting M, Kulkarni A, Brewer NT, Zimet GD. Pediatrician-Parent Conversations About Human Papillomavirus Vaccination: An Analysis of Audio Recordings. *Journal of Adolescent Health*. 2017;61:246–251. [PubMed: 28455129]
28. Shay LA, Street RLJ, Baldwin AS, et al. Characterizing safety-net providers' HPV vaccine recommendations to undecided parents: A pilot study. *Patient education and counseling*. 2016;99(9):1452–1460. [PubMed: 27401828]

29. Dempsey AF, O'Leary ST. Human Papillomavirus Vaccination: Narrative Review of Studies on How Providers' Vaccine Communication Affects Attitudes and Uptake. *Academic Pediatrics*. 2018;18(2):S23–S27. [PubMed: 29502633]
30. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of Physician Communication about Human Papillomavirus Vaccine: Findings from a National Survey. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2015;24(11):1673–1679.
31. Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic review. *Human vaccines & immunotherapeutics*. 2016;12(6):1454–1468. [PubMed: 26838681]
32. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. *Pediatrics*. 2016.
33. Dempsey AF, Pyrznowski J, Lockhart S, et al. Effect of a Health Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized Clinical Trial. *JAMA pediatrics*. 2018;172(5):e180016. [PubMed: 29507952]
34. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. *World journal of hepatology*. 2015;7(18):2127–2132. [PubMed: 26328023]
35. Centers for Disease Control and Prevention. Hepatitis B Vaccination: What Everyone Should Know. In. Atlanta, GA 2017.
36. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years - United States, 2017. *MMWR Morbidity and mortality weekly report*. 2018;67(33):909–917. [PubMed: 30138305]
37. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. 2018;67(1):1–31.
38. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. *JAMA : the journal of the American Medical Association*. 2016;315(11):1149–1158. [PubMed: 26978210]
39. Zimet GD, Perkins SM, Winston Y, Kee R. Predictors of first and second dose acceptance of hepatitis B vaccine among STD clinic patients. *International Journal of STD and AIDS*. 2008;19:246–250. [PubMed: 18482944]
40. Cohen J *Statistical power analysis for the behavioral sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
41. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior research methods*. 2007;39(2):175–191. [PubMed: 17695343]
42. Appel M, Richter T. Persuasive Effects of Fictional Narratives Increase Over Time. *Media Psychology*. 2007;10(1):113–134.
43. Moyer-Gusé E, Nabi RL. Explaining the Effects of Narrative in an Entertainment Television Program: Overcoming Resistance to Persuasion. *Human Communication Research*. 2010;36(1):26–52.
44. De Wit JBF, Das E, Vet R. What works best: Objective statistics or a personal testimonial? An assessment of the persuasive effects of different types of message evidence on risk perception. *Health Psychology*. 2008;27(1):110–115. [PubMed: 18230021]
45. Kahneman D, Tversky A. Prospect Theory: An Analysis of Decision under Risk. *Econometrica*. 1979;47(2):263–291.
46. Perkins RB, Apte G, Belizaire M, et al. Are parents or doctors the cause of low HPV vaccination rates: A qualitative study. *Journal of Adolescent Health*. 2014;54(2):S82–S83.
47. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. *Preventive medicine*. 2007;45(2–3):107–114. [PubMed: 17628649]
48. Alexander AB, Stupiansky N, Ott MA, Suah A, Shew M, Zimet GD. Parent-son decision-making about HPV vaccination. *Journal of Adolescent Health*. 2012;50(2):S69.
49. Donahue KL, Stupiansky NW, Alexander AB, Zimet GD. Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. *Vaccine*. 2014;32(31):3883–3885. [PubMed: 24844150]

50. Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: Correcting the myths and the misinformation. *Preventive medicine*. 2013;57(5):414–418. [PubMed: 23732252]
51. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. *American journal of public health*. 2013;103(1):164–169. [PubMed: 22698055]
52. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. *The Journal of adolescent health : official publication of the Society for Adolescent Medicine*. 2009;45(5):453–462. [PubMed: 19837351]
53. Kasting ML, Cox AD, Cox D, Fife KH, Katz BP, Zimet GD. The effects of HIV testing advocacy messages on test acceptance: a randomized clinical trial. *BMC medicine*. 2014;12:204. [PubMed: 25374047]

Highlights

- Message framing (gain vs. loss) makes no difference in vaccine uptake.
- A strong provider recommendation, as opposed to an offer, leads to better uptake.
- Fear of shots and fear of vaccines do not moderate vaccination behaviors.




Figure 1.
CONSORT Flow Diagram




Figure 2.
Hepatitis B Vaccine Dose Acceptance by Intervention Components




Figure 3.
Perceived Message Framing

Table 1.

Content of Message Framing Interventions

	Control	Gain-Frame	Loss-Frame
Intro	We want to remind you that hepatitis B virus can be transmitted by unprotected sex and by sharing needles. A vaccine for hepatitis B virus exists. It requires 3 shots over 6 months to be most effective at preventing infection with the hepatitis B virus	People who get the hepatitis B shot are gaining a chance to protect themselves and the ones they love.	People who don't get the hepatitis B shot are losing a chance to protect themselves and the ones they love.
Part 1		Michael/Angela felt very healthy and didn't believe s/he would be infected by the Hepatitis B virus. But s/he followed the advice of the American Medical Association and got 3 hepatitis B vaccine shots over 6 months. Because of this, s/he is protected against hepatitis B infection. Now s/he is much less likely to get sick or die from serious liver disease, and s/he can look forward to a long and healthy life, watching his/her child grow up.	Michael/Angela felt very healthy and didn't believe s/he would be infected by the Hepatitis B virus. So s/he didn't follow the advice of the American Medical Association and didn't get 3 hepatitis B vaccine shots over 6 months. Because of this, s/he is not protected against hepatitis B infection. Now s/he is much more likely to get sick or die from serious liver disease, and s/he may miss out on a long and healthy life watching his/her child grow up.
Part 2		James/Michelle decided s/he needed to protect him(her)/self and got the hepatitis B vaccine. As a result, s/he did not get infected after having sex with an infected partner. Because James/Michelle did not get infected with the hepatitis B virus, s/he did not pass it on to his/her new partner. So, his/her new partner did not get sick with hepatitis B, and now they have gained a chance for a healthy future together.	James/Michelle decided s/he didn't need to protect him(her)/self and didn't get the hepatitis B vaccine. As a result, s/he got infected after having sex with an infected partner. Because James/Michelle got infected with the hepatitis B virus, s/he passed it on to his/her new partner. So, his/her new partner got sick with hepatitis B, and now they have lost their chance for a healthy future together.

Table 2.

Intervention Group Comparisons at Baseline

Characteristic	No-Framed + Offered	No-Framed + Recommended	Loss-Framed + Offered	Loss-Framed + Recommended	Gain-Framed + Offered	Gain-Framed + Recommended
Mean Age (SD)	31.2 (9.7)	31.8 (9.8)	31.2 (9.8)	31.7 (9.4)	32.1 (10.1)	32.3 (10.6)
Gender						
% Female	40.5	37.0	38.5	39.6	40.1	42.4
Education						
% < High School	26.4	24.3	19.2	24.6	24.3	18.1
% High School Graduate	39.1	37.7	40.2	44.7	41.1	41.2
% > High School	34.4	38.0	40.5	30.7	34.6	37.8
Race						
% African American	84.3	82.0	81.1	79.5	81.8	80.9
Employment Status						
% Currently Employed	47.8	54.6	57.7	51.0	53.4	52.1
Relationship Status						
% Married/ Partnered	53.0	51.4	52.2	51.1	55.7	55.5
Annual Family Income						
% < \$10,000	50.7	42.8	42.9	47.6	44.1	41.0
% \$10,000 – \$29,000	35.4	38.0	36.2	37.5	34.1	37.3
% \$30,000	13.9	19.2	20.9	14.9	21.9	21.8
Study Site						
% Indianapolis	37.1	35.6	35.4	36.5	35.6	35.8
% Chicago Site 1	32.4	33.1	34.4	32.4	33.6	33.3
% Chicago Site 2	30.4	31.3	30.2	31.1	30.8	30.9
Mean Fear of Shots (SD)	2.8 (0.9)	2.9 (1.0)	3.0 (1.0)	2.9 (1.0)	2.8 (1.0)	2.9 (1.0)
Mean Fear of Vaccine (SD)	2.4 (0.6)	2.4 (0.6)	2.5 (0.6)	2.4 (0.6)	2.4 (0.6)	2.4 (0.6)